CABOMETYX
- Product NDC
- 42388-025
- 11-digit product format
- 423880025
- Labeler code
- 42388
- Product ID
- 42388-025_e8cdcbdc-d863-4d48-af3e-a8926b9ab017
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- cabozantinib
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Exelixis, Inc.
- Application
- NDA208692
- Marketing category
- NDA
- Marketing start
- 2016-04-25
- Substance
- CABOZANTINIB S-MALATE
- Active strength
- 40 mg/1
- Pharmacologic classes
- Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- CABOMETYX
- Listing expiration
- 2026-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| CABOZANTINIB S-MALATE | 40 mg/1 |
Harmonized Identifiers#
Field, Values table| Field | Values |
|---|
| Unii | DR7ST46X58 |
| Rxcui | 1790161, 1790167, 1790169, 1790171, 1790173, 1790175 |
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
NDC, Effective, Action table| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|
| 42388-025-26 | 2025-02-04 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
| 42388-025-26 | 2025-02-04 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
| 42388-025-37 | 2025-02-04 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
| 42388-025-37 | 2025-02-04 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
| 42388-025-46 | 2025-02-04 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
| 42388-025-46 | 2025-02-04 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
| 42388-025-57 | 2025-02-04 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
| 42388-025-57 | 2025-02-04 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
| 42388-025-26 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
| 42388-025-26 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
| 42388-025-37 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
| 42388-025-37 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
| 42388-025-46 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
| 42388-025-46 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
| 42388-025-57 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
| 42388-025-57 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-599a-d83d-e063-dadaa90ab31f | These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX. CABOMETYX ® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012 |
DailyMed Package Descriptions#
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 42388-025 | CABOMETYX (CABOZANTINIB) TABLET [EXELIXIS, INC.] | 16 | Current NDC, Legacy NDC, 6 package rows | 20250406_3850cce2-6137-42e5-a792-d318c4a4b3b5.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 42388-025-26 | 42388002526 | 30 TABLET in 1 BOTTLE (42388-025-26) | 30 tablet | 2016-04-25 | 0000-00-00 | No | No | Current |
| 42388-025-37 | 42388002537 | 15 TABLET in 1 BOTTLE (42388-025-37) | 15 tablet | 2019-02-27 | 0000-00-00 | Yes | No | Current |
| 42388-025-46 | 42388002546 | 1 BOTTLE in 1 CARTON (42388-025-46) / 30 TABLET in 1 BOTTLE | 1 bottle | 2023-01-09 | | No | No | Historical |
| 42388-025-57 | 42388002557 | 1 BOTTLE in 1 CARTON (42388-025-57) / 15 TABLET in 1 BOTTLE | 1 bottle | 2023-01-09 | | Yes | No | Historical |